🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

AngioDynamics, Inc. ANGO R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.angiodynamics.com

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

READ MORE ›
$11.48
+12.55% 1Y

Market & Price

Market Cap
$474.34M
Current Price
$11.48
High / Low (52W)
$13.64 / $8.40
Beta
0.37

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
1.41
Book Value
$4.16
Price to Book
2.76
P/S
1.51
EV/EBITDA
-686.03
Dividend Yield
-

Profitability & Returns

ROCE
-11.80%
ROE
-17.47%
ROA
-4.68%
Profit Margin
-10.01%
Op Margin
-8.20%
EPS (Latest Qtr)
$-0.19
EPS (TTM)
$-0.76

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
1.26
Current Ratio
2.35
Debt
$11.39M
Total Assets
$280.14M
Current Assets
$168.32M
Working Capital
$92.13M

Ownership

Promoter Holding
12.28%
Chg in Prom Hold
0.00%
FII / Inst Holding
94.68%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$452.09M
Total Revenue (TTM)
$313.72M
EBITDA
$-659.00K
Free Cash Flow
$13.94M
Operating Cash Flow
$4.45M
Shares Outstanding
41.32M
Gross Margin
54.30%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-2.57%
Profit 5Y
-9.35%
Revenue (YoY)
8.90%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Revenue declined at -2.6% CAGR over 5 years.
  • Earnings shrank at -9.3% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANGO AngioDynamics, Inc. R2K 11.48 - $474.34M - -11.80% -17.47% -2.57% -9.35%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Aug 2015Nov 2015Feb 2016May 2016Aug 2016Nov 2016Feb 2017May 2017Aug 2017Nov 2017Feb 2018May 2018Aug 2018Nov 2018Feb 2019May 2019Aug 2019Nov 2019Feb 2020May 2020Aug 2020Nov 2020Feb 2021Aug 2021Nov 2021Feb 2022May 2022Aug 2022Nov 2022Feb 2023Aug 2023Nov 2023Feb 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026
Revenue --------------------70.22M72.77M71.18M76.97M78.28M73.97M-81.54M85.43M80.71M78.68M79.07M75.18M--72.00M80.16M75.71M79.43M78.42M
Cost of Revenue -----------------------------------33.15M37.94M33.85M34.65M36.94M
Gross Profit 43.37M45.88M43.53M41.53M45.03M45.01M43.79M42.34M33.04M34.70M37.50M38.62M35.95M40.55M38.16M41.33M38.22M41.54M40.30M30.21M35.76M40.17M38.53M40.14M40.55M38.58M-42.30M45.08M40.50M40.06M40.26M35.86M--38.86M42.22M41.86M44.78M41.48M
Operating Expenses -----------------------------------45.51M45.85M49.76M47.27M47.91M
Operating Income 212.00K565.00K1.97M-3.57M15.59M5.14M-140.00K1.12M4.86M--6.13M-2.53M-3.67M--828.00K-3.42M-6.24M--5.12M-4.84M-3.74M-8.10M-8.68M-5.29M--13.30M-8.12M-8.93M35.03M-13.12M-199.90M---6.65M-3.63M-7.90M-2.49M-6.43M
EBITDA ------------------------------------329.00K2.20M-1.88M3.26M-838.00K
Interest Expense ----------------------------------------
Pretax Income ------------------------------------4.41M-6.11M-10.84M-6.36M-8.07M
Tax Provision ------------------------------------2.00K-60.00K65.00K-5.00K12.00K
Net Income -775.00K-334.00K594.00K-43.08M1.30M13.73M2.89M-12.91M-35.00K249.00K14.02M2.10M-469.00K2.14M796.00K58.87M-1.27M-2.74M-5.71M-157.07M-4.27M-4.27M-3.54M-6.97M-8.35M-4.96M-13.00M-13.00M-8.49M-9.48M45.88M-29.05M-187.74M---4.41M-6.05M-10.90M-6.35M-8.08M
Diluted EPS -0.02-0.010.02-1.190.040.370.08-0.350.000.010.370.06-0.010.060.021.54-0.03-0.07-0.15-4.14-0.11-0.11-0.09-0.18-0.21-0.13--0.33-0.21-0.241.15-0.72-4.67---0.11-0.15-0.26-0.15-0.19
R&D Expense 6.13M6.18M5.81M-6.71M5.91M5.95M-6.44M6.11M6.46M-7.37M7.08M6.92M-6.29M7.76M8.39M-9.01M9.71M8.56M7.39M8.20M7.28M-8.33M6.84M6.85M7.94M8.66M8.19M6.29M6.43M6.91M-6.42M7.77M7.08M

Profit & Loss (Annual)

Figures in USD.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Revenue ----------264.16M-316.22M338.75M303.91M292.50M
Cost of Revenue ------------150.49M164.51M149.22M134.79M
Gross Profit 126.97M125.57M125.31M168.51M180.17M175.80M174.32M143.95M143.86M156.00M150.27M-165.73M174.25M154.70M157.71M
Operating Expenses ------------183.95M192.93M188.54M181.77M
Operating Income 20.87M11.90M-5.24M5.24M10.49M-3.45M1.02M-11.18M-14.17M-9.40M-167.10M--18.22M-18.68M-33.84M-24.06M
EBITDA ------------11.13M12.19M-6.13M1.74M
Interest Expense -----------861.00K688.00K2.70M--
Pretax Income -------------29.95M-54.44M-191.64M-34.03M
Tax Provision -------------3.40M-2.00M-7.29M-39.00K
Net Income 12.31M8.08M-5.33M-1.05M2.35M-3.39M-43.59M5.01M16.34M61.34M-166.79M--26.55M-52.44M-184.35M-33.99M
Diluted EPS 0.500.32-0.20-0.030.07-0.09-1.210.140.441.64-4.39--0.68-1.33-4.59-0.83
R&D Expense 19.27M21.37M20.51M26.09M28.12M26.59M25.05M24.15M24.34M28.26M29.68M36.39M30.74M29.88M31.51M26.22M

Compounded Sales Growth

5 Years:-2.57%
1 Year:8.90%

Compounded Profit Growth

5 Years:-9.35%
1 Year:-

Stock Price Performance

1 Year:+12.55%
6 Months:-7.42%
3 Months:+0.35%
1 Month:+7.69%

Balance Sheet (Annual)

Figures in USD.

Metric May 2009May 2010May 2011May 2012May 2013May 2014Aug 2014Nov 2014Feb 2015May 2015Aug 2015Nov 2015Feb 2016May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Total Assets --437.31M719.90M790.56M798.58M796.17M798.73M783.39M773.06M772.00M760.44M753.61M726.19M707.96M705.47M836.44M594.21M-552.75M532.64M317.67M280.14M
Current Assets -------------------143.34M163.54M193.25M168.32M
Cash & Equivalents 27.91M58.76M45.98M23.74M16.11M18.39M---18.39M---32.33M47.54M74.10M227.64M54.44M-28.82M44.62M76.06M55.89M
Inventory -------------------51.39M55.33M60.62M62.01M
Receivables -------------------52.30M52.83M43.61M42.89M
Total Liabilities --31.68M196.60M264.24M261.69M256.58M255.49M239.82M227.96M224.82M212.72M202.82M218.97M192.93M162.88M221.62M139.34M-128.26M154.34M112.08M97.17M
Current Liabilities --25.40M53.77M62.92M65.94M63.35M57.10M59.50M60.52M60.80M60.09M61.63M66.73M71.52M57.30M73.30M51.45M-74.32M83.83M91.16M76.20M
Long Term Debt --6.28M142.50M135.00M137.66M--------91.32M86.62M124.41M-20.00M25.00M49.82M--
Total Debt ------------------20.00M33.78M64.58M4.73M-
Total Equity 372.19M391.35M405.64M523.31M526.32M536.88M539.59M543.24M543.57M545.10M547.18M547.73M550.80M507.23M515.03M542.60M614.82M454.87M-424.49M378.30M205.59M182.97M
Shares Outstanding -------------------39.54M39.98M40.80M41.61M

Cash Flows (Annual)

Figures in USD.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Operating Cash Flow 39.96M33.87M11.60M26.65M24.68M25.68M45.22M55.74M41.29M37.44M-14.55M--7.19M78.00K-28.16M-10.13M
Investing Cash Flow -11.78M-48.62M-176.23M-22.24M-16.45M-12.74M-7.57M-2.55M-3.66M82.55M-63.34M--19.31M-9.75M123.72M-10.18M
Financing Cash Flow 2.72M1.92M142.34M-6.29M-14.02M-10.46M-23.66M-37.98M-11.55M33.93M-95.24M-7.68M25.42M-64.25M-255.00K
Capital Expenditure -5.04M-2.96M-2.49M-12.12M-11.17M-11.38M-2.33M-3.00M-2.39M-3.12M-7.24M--4.30M-4.35M-5.77M-4.46M
Free Cash Flow 34.92M30.91M9.11M14.53M13.51M14.30M42.89M52.74M38.90M34.32M-21.79M--11.49M-4.27M-33.93M-14.59M
Net Change in Cash -------------18.82M15.75M31.31M-20.56M
Share Buybacks --2.10M000013.56M00---001.67M
Dividends Paid --000-----------

Ratios (Annual)

Figures in %.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Gross Margin % ----------56.9%-52.4%51.4%50.9%53.9%
Operating Margin % -----------63.3%--5.8%-5.5%-11.1%-8.2%
Net Margin % -----------63.1%--8.4%-15.5%-60.7%-11.6%
ROE % 3.1%2.0%-1.0%-0.2%0.4%-0.6%-8.6%1.0%3.0%10.0%-36.7%--6.3%-13.9%-89.7%-18.6%
ROCE % -2.9%-0.8%0.7%1.4%-0.5%0.2%-1.8%-2.2%-1.2%-30.8%--3.8%-4.2%-14.9%-11.8%

Shareholding Pattern

Insiders
12.28%
Institutions
94.68%
Public Float
107.93%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.92% 3.69M $42.31M
2 Point72 Asset Management, L.P. 7.70% 3.18M $36.53M
3 Systematic Financial Management, L.P. 5.94% 2.45M $28.17M
4 Broadfin Holdings LLC 5.01% 2.07M $23.76M
5 Armistice Capital, LLC 4.52% 1.87M $21.46M
6 Vanguard Capital Management LLC 4.18% 1.73M $19.82M
7 Royce & Associates LP 3.70% 1.53M $17.55M
8 Weber Capital Management LLC /ADV 3.32% 1.37M $15.76M
9 State Street Corporation 3.23% 1.33M $15.31M
10 Bastion Asset Management Inc. 3.18% 1.31M $15.07M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANGO

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks